Context Therapeutics Inc. (NASDAQ:CNTX) Receives $5.50 Average PT from Analysts

Context Therapeutics Inc. (NASDAQ:CNTX - Get Free Report) has been given a consensus rating of "Buy" by the six analysts that are covering the stock, Marketbeat Ratings reports. Five analysts have rated the stock with a buy recommendation and one has given a strong buy recommendation to the company. The average 12 month price objective among brokers that have updated their coverage on the stock in the last year is $5.50.

A number of brokerages have issued reports on CNTX. D. Boral Capital restated a "buy" rating and set a $9.00 target price on shares of Context Therapeutics in a research report on Thursday, May 8th. Piper Sandler reissued an "overweight" rating and set a $4.00 target price (down from $4.50) on shares of Context Therapeutics in a report on Thursday, June 26th. Finally, William Blair reaffirmed an "outperform" rating on shares of Context Therapeutics in a research report on Tuesday, April 29th.

Context Therapeutics Price Performance

Context Therapeutics stock traded up $0.01 during trading hours on Monday, hitting $0.84. The company had a trading volume of 199,068 shares, compared to its average volume of 190,974. Context Therapeutics has a one year low of $0.49 and a one year high of $2.75. The firm has a market cap of $75.42 million, a PE ratio of -2.71 and a beta of 1.88. The firm has a 50-day moving average of $0.67 and a 200 day moving average of $0.78.

Context Therapeutics (NASDAQ:CNTX - Get Free Report) last posted its quarterly earnings data on Wednesday, May 14th. The company reported ($0.05) earnings per share for the quarter, hitting the consensus estimate of ($0.05). As a group, research analysts expect that Context Therapeutics will post -0.51 earnings per share for the current year.

Insiders Place Their Bets

In related news, CEO Martin A. Lehr acquired 100,000 shares of the business's stock in a transaction that occurred on Monday, June 9th. The shares were bought at an average cost of $0.70 per share, with a total value of $70,000.00. Following the completion of the purchase, the chief executive officer directly owned 920,190 shares in the company, valued at $644,133. The trade was a 12.19% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available at this link. Also, CFO Jennifer Lynn Minai-Azary bought 40,010 shares of the firm's stock in a transaction on Friday, June 6th. The shares were purchased at an average cost of $0.64 per share, with a total value of $25,606.40. Following the transaction, the chief financial officer directly owned 80,010 shares in the company, valued at approximately $51,206.40. This trade represents a 100.03% increase in their position. The disclosure for this purchase can be found here. In the last quarter, insiders have bought 160,010 shares of company stock worth $107,206. 2.80% of the stock is owned by company insiders.

Institutional Investors Weigh In On Context Therapeutics

Several large investors have recently modified their holdings of CNTX. Jane Street Group LLC bought a new stake in Context Therapeutics during the fourth quarter valued at $29,000. Citadel Advisors LLC acquired a new stake in Context Therapeutics during the fourth quarter worth approximately $31,000. Shay Capital LLC bought a new stake in Context Therapeutics in the fourth quarter worth approximately $52,000. Landscape Capital Management L.L.C. bought a new stake in Context Therapeutics in the fourth quarter worth approximately $94,000. Finally, Walleye Capital LLC lifted its stake in Context Therapeutics by 51.7% in the fourth quarter. Walleye Capital LLC now owns 166,306 shares of the company's stock valued at $175,000 after buying an additional 56,651 shares during the period. 14.03% of the stock is currently owned by institutional investors and hedge funds.

Context Therapeutics Company Profile

Context Therapeutics Inc, a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy.